Vitamin C sensitizes BRAF^V600E thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032.

ABSTRACT:

Background

BRAFV600E mutation is the most common mutation in thyroid cancer. It strongly activates MAPK/ERK pathway and indicates an invasive subtype of thyroid cancer. PLX4032 is a selective oral inhibitor of the BRAFV600 kinase although with limited effect in treating this panel of thyroid cancer, due to the feedback activation of MAPK/ERK as well as PI3K/AKT pathways. It was investigated that Vitamin C plays a positive role in inhibiting these pathways in thyroid cancer. However, whether Vitamin C could enhance the antitumor effect of PLX4032 remains largely unclear.

Methods

The antitumor efficacy of combination therapy with PLX4032 and Vitamin C on BRAF^MT thyroid cancer cell was assessed by the MTT assay, EdU assay and colony formation, Chou-Talalay way was em

SUBMITTER: Su X 

PROVIDER: S-EPMC7816401 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature